Quantification of Imidapril in Human Plasma using the LC-MS/MS Method for Bioequivalence and Pharmacokinetic Studies

Author(s): Su-Hee Lee, Hyun-Jin Kim, Shin-Hee Kim, Yoo-Sin Park, Min-A Kang, Do-Wan Kim, Ju-Seop Kang.

Journal Name: Current Pharmaceutical Analysis

Volume 12 , Issue 2 , 2016

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

We developed the LC-MS/MS method through a comparison of the pharmacokinetic characteristics of imidapril to assess the bioequivalence of two types of imidapril in 31 normal Korean subjects. Blood sample were collected at 13 time points for 12 h after dosing and detected by LC-MS/MS in the range of 0.2-100 ng/mL with LLOQ of 0.2 ng/mL. Pharmacokinetic parameters analyzed from the plasma samples and data from the reference and test drugs in the plasma were represented such as AUC0-t (142.31 vs 131.95 ng•h/mL), AUC0-infinity (143.85 vs 133.72 ng•h/mL), Cmax(33.28 vs 30.46 ng/mL), Tmax(2.0 vs 1.9 h), half-life(1.6 vs 1.6 h), extrapolation (1.35 vs 1.46%), and Ke (0.46 vs 0.45 h-1). Pharmacokinetic parameters with a 90% confidence interval (CI) were 0.873–1.084 for AUC0-t and 0.863–1.149 for Cmax. Pharmacokinetic parameters with 90% CI were included within the bioequivalence range of 80–125% of the KFDA guidelines. Therefore, the two imidapril types were found to be bioequivalent during the fasting state in normal subjects.

Keywords: Angiotensin-converting enzyme (ACE) inhibitor, bioequivalence, imidapril, korean volunteers, LC-MS/MS, Pharmacokinetics.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 12
ISSUE: 2
Year: 2016
Page: [107 - 113]
Pages: 7
DOI: 10.2174/1573412911666150723232335

Article Metrics

PDF: 53
HTML: 2

Special-new-year-discount